CVS CVS Health Corporation Common Stock

NYSE · Health Care · ดูใน SEC EDGAR ↗
$94.44
ราคา · ส.ค. 18, 2026
ข้อมูลพื้นฐาน ณ วันที่ ส.ค. 5, 2026

เกี่ยวกับ CVS Health Corporation Common Stock ภาพรวมบริษัทจาก Wikipedia

CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.

อ่านเพิ่มเติม

CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.

History

1960s

The first Consumer Value Store (CVS), selling health and beauty products, was founded in 1963, in Lowell, Massachusetts, by brothers Stanley and Sidney Goldstein and Ralph Hoagland. By 1964, CVS had 17 stores that sold primarily beauty products. In 1967, CVS opened its first stores with pharmacy departments in Warwick, Rhode Island, and Cumberland, Rhode Island. CVS was sold to Melville Corporation in 1969.

1970s

By 1970, CVS was operating 100 stores in New England and the Northeast. In 1972, CVS acquired 84 Clinton Drug and Discount Stores. This purchase introduced CVS to the Midwest with stores in Indiana. During 1977, CVS acquired 36 New Jersey–based Mack Drug stores.

1980s

In 1983, CVS began providing home health care for hemophilia. The company acquired Heartland Drug in 1988, a small pharmacy company in the Boston area giving it stores in the Boston metro including Watertown Square and Harvard Square.

1990s

CVS acquired 500 Peoples Drug stores in 1990, establishing the company in new mid-Atlantic markets including Washington, D.C., Pennsylvania, Maryland and Virginia. In 1994, it launched PharmaCare, a pharmacy benefit management (PBM) company. CVS became a standalone company trading on the New York Stock Exchange under the "CVS" ticker in 1996. Stanley Goldstein was the company's first chairman. CVS acquired over 2,500 Revco drug stores, establishing the company in additional Midwestern, Southeastern and Eastern states in 1997.

In 1998, the company acquired 207 stores from Arbor Drugs, giving CVS its first stores in Michigan. A year later, CVS acquired Soma.com, the first online pharmacy, and renamed it CVS.com to become the first fully integrated online and brick-and-mortar pharmacy offering to consumers.

2000s

In 2000, CVS acquired Stadtlander pharmacy from Bergen Brunswig Corporation, making CVS ProCare the largest specialty pharmacy in the U.S. at the time. In 2001, CVS launched the ExtraCare loyalty card program. Within a year, 30 million customers enrolled to earn rewards and receive discounts. CVS purchased 1,268 Eckerd drug stores and Eckerd Health Services, Eckerd's PBM/Mail-order pharmacy business, from JCPenney in 2004. The purchase expanded the company's footprint in Texas, Florida and other southern states.

2006 saw CVS acquiring 700 freestanding drug store operations of supermarket chain Albertsons, including stores trading under the Osco Drug and Sav-On Drugs banners. That same year, it acquired Minneapolis-based MinuteClinic. CVS Corporation and Caremark Rx, Inc. completed their transformative merger in 2007, creating CVS Caremark, an integrated pharmacy services provider, and the corporate headquarters remained in Woonsocket, RI. Tom Ryan, the chairman and CEO of CVS remained president and CEO of CVS Caremark Corporation, while Caremark's Edwin Crawford became the chairman of the board. CVS Caremark acquired 541 stores from Longs Drugs Stores Corp in California, Hawaii, and Nevada in 2008.

2010s

2011 saw Larry Merlo succeeding Tom Ryan as president and CEO of CVS Caremark. Merlo joined CVS/pharmacy in 1990, through the acquisition of Peoples Drug. On September 3, 2014, it was announced that CVS, as of midnight Tuesday September 2, 2014, would no longer sell tobacco products at all of its 7,700 locations nationwide, a month earlier than planned. It also announced it would change its corporate name to CVS Health to reflect "its broader health care commitment" and a desire to change the future health of Americans, although all retail stores would continue to be called "CVS/pharmacy", unless they did not contain a pharmacy, in which case they are just signed CVS. CVS Caremark acquired Coram in 2014, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc. That same year, the company acquired 33 Miami-based Navarro Discount Pharmacy stores, the largest Hispanic-owned drugstore chain the United States. A year later in 2015, it acquired Omnicare, provider of pharmacy services to long-term care facilities. CVS Health acquired Target's 1,600+ pharmacies and retail medical clinics inside Target stores that same year. CVS has begun operating them through a store-within-a-store format.

CVS announced they would be installing 25 vending machines in high traffic areas like, bus terminals, airports, and college campuses in 2017. The first kiosks will be located in LaGuardia Airport and Boston's South Station Bus Terminal and will carry personal items such as toothpaste, deodorant, batteries, and healthy snack foods. In December, CVS announced they agreed to buy health insurer Aetna for about $207 per share, broken down into $145 in cash and the rest in stock, in December 2017. If approved, it would allow CVS to provide a broad range of health services to Aetna's 22 million medical members. On December 5, 2017, The Wall Street Journal reported that there was still a $69 billion deal pending between CVS and Aetna, so long as it received government approval. CVS CEO Larry Merlo had been named to run the combined company. In November 2018, CEO Larry Merlo told USA Today that the drugstore chain plans to renovate its stores to focus more on health care and less on retail following its merger with the health insurance company Aetna. The new strategy is to offer medical services along with prescription drugs, among other products. On June 4, 2019, USA Today reported on the planned expansion of a CVS Health store concept called HealthHUB to 1,500 locations by the end of 2021. The concept, launched in the Houston area in early 2019, realigns CVS retail outlets with a stronger focus on health care services. HealthHUB stores dedicate at least 20% of their floor space to health care services such as yoga classes and enlarged Minute Clinic spaces to offer more health assessments. To accommodate HealthHUB, CVS locations will reduce the floor space currently devoted to slower-selling merchandise, such as greeting cards. The store conversions to the HealthHUB format was paused in March 2020, due to the COVID-19 pandemic.

2020s

In February 2020, CVS announced changes to its board of directors, whose size was reduced from 16 to 13 directors. On November 18, 2021, the company announced that it plans to close 900 stores nationwide over the next three years because of what executives described as changes in consumer shopping behavior, population, and the future of health care needs. The closures would represent approximately 10 percent of stores in the US. On November 23, 2021, federal jury found that CVS, along with Walgreens and Walmart, "had substantially contributed to" the opioid crisis.

On December 2, 2021, CVS announced a strategic partnership with Microsoft to improve personalized care and digital health. In September 2022, CVS Health announced that it reached an agreement to buy at-home health company Signify Health for roughly $8 billion. It came one month after it announced a plan to move into primary care by the end of the year. On February 8, 2023, the company announced it has entered into a definitive agreement to acquire Oak Street Health in an all-cash transaction at $39 per share, representing an enterprise value of approximately $10.6 billion. The merger was completed in May 2023.

Finances

Subsidiaries and assets

Aetna

Aetna Inc. is an American managed health care company that sells traditional and consumer directed health care insurance and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans, primarily through employer-paid (fully or partly) insurance and benefit programs, and through Medicare.

CVS Pharmacy

CVS Pharmacy is one of the largest retail pharmacy chains in the United States, with 9,600 stores located in all 50 states, the District of Columbia, and Puerto Rico, operating primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy and Drogaria Onofre names. CVS Pharmacy fills more than one of every five prescriptions in the United States, and 85% of U.S. population lives within 10 miles of a CVS Pharmacy. The ExtraCare loyalty program boasts over 70 million cardholders, making it the largest retail loyalty program in the country.

MinuteClinic

MinuteClinic retail medical clinics operate inside CVS Pharmacy locations within the United States. It is the largest walk-in medical clinic in the United States, with over 1,100 locations in 33 states and the District of Columbia. More than 50 percent of the U.S. population now lives within 10 miles of a MinuteClinic.

CVS Caremark

CVS Caremark provides comprehensive prescription benefit management services including mail order pharmacy services, specialty pharmacy and infusion services, plan design and administration, formulary management and claims processing. The company's clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans and other sponsors of health benefit plans and individuals throughout the United States. CVS Caremark manages the dispensing of prescription drugs for more than 75 million plan members through five mail order pharmacies, specialty pharmacies, long-term care pharmacies and national network of more than 68,000 retail pharmacies, consisting of approximately 41,000 chain pharmacies and 27,000 independent pharmacies.

CVS Media Exchange

CVS Media Exchange (CMX) is CVS Health's retail media network, launched in 2020.

CVS Specialty

CVS Specialty is the specialty pharmacy division that provides specialty pharmacy services for individuals with chronic or genetic diseases who require complex and expensive drug therapies. CVS Health operate 24 retail specialty pharmacy stores and 11 specialty mail order pharmacies, making them the largest specialty pharmacy in the United States.

Longs Drugs

Longs Drugs is a retail pharmacy chain with approximately 40 drug stores throughout the state of Hawaii. Prior to its acquisition by CVS in 2008, it was a chain of over 500 stores located primarily on the west coast of the United States. The stores in states other than Hawaii were rebranded to CVS.

Navarro Discount Pharmacies

Navarro Discount Pharmacies is a pharmacy chain, photo service, and pharmacy benefit manager in the United States. The company was acquired by CVS Health in September 2014, and is operated as a separate brand of CVS Health. The company mainly operates in Miami-Dade and Broward Counties and currently has 33 stores.

Accordant

Accordant provides rare disease case management and care management services for patients with rare, chronic diseases and their caregivers. Clients are primarily health plans, employers, and third party administrators (TPAs). The company is operated as a wholly owned subsidiary of CVS Health Corporation.

Coram

Coram is one of the nation's largest providers of infusion services, clinical and compliance monitoring and individual patient counseling and education. Coram cares for 140,000 patients annually through a national network of more than 85 locations as well as the largest home infusion network in the United States. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.

Omnicare

Omnicare is a provider of pharmacy services to the long-term care market for patients in skilled nursing and assisted living facilities throughout North America. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.

HealthHUB

HealthHUBs operate inside of select CVS Pharmacy locations and offer a variety of additional services in addition to traditional CVS locations. HealthHUB locations offer and expanded variety of Sleep Apnea, Durable Medical Equipment, Home and Health technology, and compression therapy. HealthHUBs are staffed by Care Concierges who are experts in HealthHub products and services. In addition, MinuteClinic locations that are HealthHub stores have expanded services and hire Medical Assistants, Registered Nurses, and Licensed Practical and Vocational Nurses to help support the Nurse Practitioners and Physician Assistants.

Store brands and private label brands

CVS Health offers a number of over-the-counter private label brands in their retail pharmacy stores, including grocery brands Gold Emblem™ and Gold Emblem Abound™; household products under the Total Home name; preservative-free vitamins and supplements under the Radiance PLATINUM line; and beauty and skin products through the Beauty 360, Nuance Salma Hayek, Makeup Academy, Skin+Pharmacy, Blade and Essence of Beauty lines.

Tobacco products removed from stores

On February 5, 2014, CVS announced that the company would discontinue the sale of all tobacco and cigarette products from their stores by October 1, 2014. In a statement explaining the change, CVS president and CEO Larry J. Merlo said, "We came to the decision that cigarettes and providing health care just don't go together in the same setting."

Criticism and controversy

Health and Medicare fraud

In the late 1980s and early 1990s, Caremark RX was involved in a number of health fraud and Medicare fraud scandals.

The combined price to settle this dispute with the U.S. Government cost the company over $250 million.

Elensys

In 1998, The Washington Post reported that CVS Corporation appeared to be sharing prescription drug information with the Woburn, Massachusetts, based marketing company, Elensys. According to the Post, Elensys received information on specific prescription drugs that individual CVS customers had purchased and used this information to send targeted direct mailings urging customers to renew prescriptions and promoting other products in which they might be interested. CVS and Elensys argued that there were no privacy issues because Elensys was acting solely as a contractor to CVS, and because the purpose of the mailings was to educate consumers. CVS claimed that it never shared customers' medical histories with Elensys (despite The Washington Post's indirect evidence that they had). George D. Lundberg, editor of the Journal of the American Medical Association, called the practice "a gross invasion" of privacy. Following a firestorm of criticism and complaints by consumers, CVS discontinued the relationship with Elensys, and moved the practice in-house.

Trio Drugs Lawsuit

On August 22, 2001, CVS Corp was sued for purchasing Trio Drugs' confidential records.

Boston prescriptions

During 2005, a series of prescription mistakes came to light in some of CVS Corporation's Boston-area stores. An investigation confirmed 62 errors or quality problems going back to 2002. In February 2006, the state Board of Pharmacy announced that the non-profit Institute for Safe Medication Practices (ISMP) would monitor all Massachusetts stores for the next two years.

Restatements

On November 15, 1999, CVS announced a restatement of its financial results for 1997, and 1998, following a Securities and Exchange Commission review of acquisition-related charges.

On February 25, 2005, CVS said it was reducing its previously announced fourth-quarter earnings by $40.5 million, to reflect the way it accounted for leased properties in its results.

Pharmaceutical kickbacks

In 2005, Caremark Rx paid $137.5 million to settle federal lawsuits filed by whistleblowers that accused a company it acquired in 2003, of improper dealings with pharmaceutical manufacturers.

The lawsuits said that the acquired company, AdvancePCS, accepted kickbacks from drug makers to promote their products over those of rivals under contracts with government programs including the Federal Employees Health Benefit Program, the Mail Handlers Health Benefit Program and Medicare health maintenance plans.

There was no admission of wrongdoing by Caremark or AdvancePCS.

CVS Caremark Corp. has changed their practices. The formulary revision process considers manufacturer rebates, payments from drug manufacturers for low placement on PBM (Pharmacy Benefit Manager) formularies, along with average wholesale price (AWP), drug availability, and bulk discounts when choosing at which co-pay a brand name drug should be placed.

Deceptive business practices

In February 2008, CVS settled a large civil lawsuit for deceptive business practices. The Kaiser Family Foundation reported:

CVS has agreed to a $38.5 million settlement in a multi-state civil deceptive-practices lawsuit against pharmacy benefit manager Caremark filed by 28 attorneys general, the Chicago Tribune reports. The attorneys general, led by Lisa Madigan (D) of Illinois and Douglas Ganslar (D) of Maryland, allege that Caremark "engaged in deceptive business practices" by informing physicians that patients or health plans could save money if patients were switched to certain brand-name prescription drugs (Miller, Chicago Tribune, 2/14).

However, the switch often saved patients and health plans only small amounts or increased their costs, while increasing Caremark's profits, Connecticut Attorney General Richard Blumenthal (D) said (Levick, Hartford Courant, 2/15). Pennsylvania Attorney General Tom Corbett (R) said the Pharmacy Benefit Manager (PBM), kept discounts and rebates that should have been passed on to employers and patients (Levy, AP/San Francisco Chronicle, 2/14). In addition, Caremark did not "adequately inform doctors" of the full financial effect of the switch and did not disclose that the switch would increase Caremark's profits, the lawsuit alleges (Chicago Tribune, 2/14).

...The settlement prohibits CVS from requesting prescription drug switches in certain cases, such as when the cost to the patient would be higher with the new prescription drug; when the original prescription drug's patent will expire within six months; and when patients were switched from a similar prescription drug within the previous two years (Hartford Courant, 2/15). Patients also have the ability to decline a switch from the prescribed treatment to the prescription offered by the pharmacy under the settlement, Madigan said (Bloomberg News/The Philadelphia Inquirer, 2/15).

Rhode Island Senate corruption case

In 2008, two former CVS executives, John R. "Jack" Kramer and Carlos Ortiz, were charged with 20 counts of mail fraud, bribery and conspiracy in relation to Operation Dollar Bill, a probe of corruption in the Rhode Island General Assembly. Kramer and Ortiz hired former state senator John Celona, who currently is serving 2+1⁄2 years on corruption charges involving CVS and other companies, as a media consultant for $12,000 a year. Celona was known for walking out on a pharmacy choice vote in the state senate while on the CVS payroll. Despite originally claiming CVS never bought any favors in his own trial, he testified against Kramer and Ortiz as the prosecution's star witness. On May 31, 2008, Kramer and Ortiz were acquitted on all counts. One juror went on the record as saying "My perception living in Rhode Island all my life is, 'Yeah, this probably did go on', but I didn't see any proof beyond a reasonable doubt that CVS did this."

FTC charges of privacy violations

On February 18, 2009, CVS Caremark agreed to settle Federal Trade Commission charges that it failed to take reasonable and appropriate security measures to protect the sensitive financial and medical information of its customers and employees, in violation of federal law. In a separate but related agreement, the company's pharmacy chain also has agreed to pay $2.25 million to resolve Department of Health and Human Services allegations that it violated the Health Insurance Portability and Accountability Act (HIPAA).

Business practices under investigation

On May 4, 2010, CVS Caremark Corp. announced that its business practices were being investigated by a group of 24 states, along with the District of Columbia and Los Angeles County. At issue is the post-merger relationship between CVS and Caremark. In addition, the company had earlier acknowledged in a filing with the Securities and Exchange Commission (SEC) that it had received a subpoena from the Office of Inspector General of the United States Department of Health and Human Services, requiring the company to provide information regarding the incentives the company provides to customers who transfer their prescriptions to CVS, including gift cards, goods and other incentives.

DEA investigation into oxycodone diversion

According to the U.S. Justice Department, in 2011, CVS pharmacies in Sanford, Florida, ordered enough painkillers to supply a population eight times its size. Sanford has a population of 53,000 but the supply would support 400,000. According to the Drug Enforcement Administration, in 2010, a single CVS pharmacy in Sanford ordered 1.8 million Oxycodone pills, an average of 137,994 pills a month. Other pharmacy customers in Florida averaged 5,364 oxycodone pills a month. DEA investigators serving a warrant to a CVS pharmacy in Sanford on October 18, 2011, noted that "approximately every third car that came through the drive-thru lane had prescriptions for oxycodone or hydrocodone". According to the DEA, a pharmacist at that location stated to investigators that "her customers often requested certain brands of oxycodone using street slang", an indicator that the drugs were being diverted and not used for legitimate pain management. In response, CVS in a statement issued February 17 in response to opioid trafficking questions from USA Today said the company is committed to working with the DEA and had taken "significant actions to ensure appropriate dispensing of painkillers in Florida".

FTC charges of deceptive pricing

On January 12, 2012, CVS Caremark paid $5 million to settle Federal Trade Commission charges that it misrepresented the prices of certain Medicare Part D prescription drugs – including drugs used to treat breast cancer symptoms and epilepsy – at CVS and Walgreens pharmacies.

Co-responsibility for opioid crisis

In September 2016, Massachusetts Attorney General Maura Healey announced a $795,000 settlement where CVS agrees to check a state database before filling the prescription for addictive opioids and other controlled substances. The settlement resolves previous allegations that the drugstore chain failed to provide pharmacists with access to the state of Massachusetts Prescription Monitoring Program (PMP). In July 2020, the attorney general of the Commonwealth of Kentucky filed a lawsuit against CVS alleging that their business practices aided in the advancing of the opioid epidemic.

In November 2021, a federal jury in Cleveland found that pharmacies operated by CVS Health, Walgreens, and Walmart were liable for contributing to the opioid epidemic in two Ohio counties. The trial lasted six weeks with the jury returning a verdict finding the Ohio pharmacies liable. It was the first trial where pharmacy companies defended themselves amidst the opioid epidemic.

In August 2022, the company was one of three chains ordered to pay damages of $650 million by a Cleveland judge in a lawsuit over opioid sales brought on by Lake County and Trumbull County in Ohio. The other two chains were Walgreens and Walmart, with two others, Rite Aid and Giant Eagle, settling before going to trial. Lawyers representing the counties claimed damages of $3.3 billion.

CFI lawsuit for consumer fraud

In July 2018, the Center for Inquiry filed a lawsuit against CVS for consumer fraud over its sale of homeopathic medicines. The filing in part contends that apart from being a waste of money, choosing homeopathic treatments to the exclusion of evidence-based medicines can result in worsened or prolonged symptoms, and in some cases, even death.

Abortion pill controversy

In January 2023, CVS announced their intentions to start dispensing mifepristone, one of the two drugs used in a medication abortion, following a change in regulations from the Food and Drug Administration. After receiving their certification to do so, CVS started offering abortion pills in jurisdictions where they are legal. The offering of abortion pills at pharmacies such as CVS has caused major political turmoil, and has resulted in numerous protests in-front of the pharmacies.

Pharmacists mistakenly cause an abortion

In October 2023, CVS mistakenly gave misoprostol, an abortion pill, to Tamika Thomas, a woman undergoing IVF who was supposed to be receiving a medication to help kick-start her pregnancy. In an interview with 8 News Now, Thomas stated she knew something was wrong when she experienced major cramping. "My cramping went beyond that. It was extreme. It was painful." As a result of the medication, Tamika lost both of her embryos. She stated, "They just killed my baby … Both my babies, because I transferred two embryos."

At the hearing, one of the pharmacists stated, "It's a human error. It was just a human error, and I'm so sorry." The two pharmacists were fined and placed on probation for one year. CVS Pharmacy was given a maximum fine of $10,000. The pharmacists will be able to return to work after one year if all conditions are met.

Animal welfare

In 2016, CVS committed to source 100% cage-free eggs by 2025, responding to pressure from animal welfare groups. In 2023, CVS announced that they reached this goal ahead of schedule, on December 31, 2022.

Community involvement and philanthropy

Since 1978, CVS Samaritan Vans have provided free roadside assistance to motorists and the community in numerous cities.

Played at the Rhode Island Country Club, the CVS Caremark Charity Classic was established to raise money for the support of non-profit agencies throughout New England. Since 1999, it has raised over $8 million for charity.

In 2024, CVS Health committed to invest nearly $35 million in equity to create two affordable housing developments in Hawai'i. A $17.5 million investment went toward the construction of 200 new affordable housing units at Kaiāulu o Kūku'ia (Lahaina, Maui), while another $17.3 million, along with The Kobayashi Group, The Ahe Group and CREA, LLC, was invested in the construction of 169 new affordable housing units at Parkway Village (Kapolei, Oahu).

แหล่งที่มา: Wikipedia (ภาษาอังกฤษ), CC BY-SA 4.0 · ดูบน Wikipedia ↗

Wikidata ↗

CVS ภาพรวมหุ้น ราคา, มูลค่าหลักทรัพย์ตามราคาตลาด, P/E, EPS, ROE, อัตราส่วนหนี้สินต่อทุน, ช่วงราคา 52 สัปดาห์

ราคา
$94.44
มูลค่าตลาด
$120.03B
P/E (TTM)
67.9
EPS (TTM)
$1.39
รายได้ (TTM)
$402.07B
อัตราเงินปันผล
2.8%
ROE
2.4%
D/E หนี้สิน/ทุน
0.0
ช่วง 52 สัปดาห์
$70 – $111

CVS กราฟราคาหุ้น OHLCV รายวันพร้อมตัวชี้วัดทางเทคนิค — แพน ซูม และปรับแต่งมุมมองของคุณ

ผลการดำเนินงาน 10 ปี แนวโน้มรายได้ กำไรสุทธิ อัตรากำไร และ EPS

รายได้และกำไรสุทธิ $402.07B
9-point trend, +117.6%
2017-12-31 2025-12-31
EPS $1.39
9-point trend, -78.4%
2017-12-31 2025-12-31
กระแสเงินสดอิสระ $7.81B
9-point trend, +28.2%
2017-12-31 2025-12-31
อัตรากำไร 0.44%
2017-12-31 2017-12-31

การประเมินมูลค่า อัตราส่วน P/E, P/S, P/B, EV/EBITDA — หุ้นมีราคาแพงหรือถูก?

ตัวชี้วัด
แนวโน้ม 5 ปี
CVS
ค่ามัธยฐานของกลุ่มอุตสาหกรรม
P/E (TTM)
5-point trend, +233.2%
67.9
42.6
P/S (TTM)
5-point trend, -46.3%
0.3
0.3
P/B
5-point trend, -26.2%
1.6
0.9
EV / EBITDA
5-point trend, -56.7%
11.8
Price / FCF (ราคาต่อกระแสเงินสดอิสระ)
5-point trend, +49.2%
15.4

ความสามารถในการทำกำไร อัตรากำไรขั้นต้น, อัตรากำไรจากการดำเนินงาน และอัตรากำไรสุทธิ; ROE, ROA, ROIC

ตัวชี้วัด
แนวโน้ม 5 ปี
CVS
ค่ามัธยฐานของกลุ่มอุตสาหกรรม
Operating Margin (อัตรากำไรจากการดำเนินงาน)
5-point trend, -74.3%
1.2%
Net Profit Margin (อัตรากำไรสุทธิ)
5-point trend, -83.8%
0.44%
-7.0%
ROA
5-point trend, -79.5%
0.70%
-10.6%
ROE
5-point trend, -78.5%
2.4%
-20.8%
ROIC
5-point trend, -62.4%
5.0%

สุขภาพทางการเงิน หนี้สิน, สภาพคล่อง, ความสามารถในการชำระหนี้ — ความแข็งแกร่งของงบดุล

ตัวชี้วัด
แนวโน้ม 5 ปี
CVS
ค่ามัธยฐานของกลุ่มอุตสาหกรรม
Debt / Equity (หนี้สินต่อทุน)
5-point trend, -100.0%
0.0
8.0
Current Ratio (อัตราส่วนสภาพคล่อง)
5-point trend, -4.8%
0.8
1.1
Quick Ratio (อัตราส่วนเงินสด)
5-point trend, +4.2%
0.6

การเติบโต การเติบโตของรายได้, EPS และกำไรสุทธิ: YoY, CAGR 3 ปี, CAGR 5 ปี

ตัวชี้วัด
แนวโน้ม 5 ปี
CVS
ค่ามัธยฐานของกลุ่มอุตสาหกรรม
Revenue YoY (รายได้ YoY)
5-point trend, +37.6%
7.8%
Revenue CAGR 3Y (CAGR รายได้ 3 ปี)
5-point trend, +37.6%
7.6%
Revenue CAGR 5Y (CAGR รายได้ 5 ปี)
5-point trend, +37.6%
8.4%
EPS YoY
5-point trend, -76.9%
-62.0%
Net Income YoY (กำไรสุทธิ YoY)
5-point trend, -77.9%
-61.7%

ตัวชี้วัดต่อหุ้น EPS, มูลค่าตามบัญชีต่อหุ้น, กระแสเงินสดต่อหุ้น, เงินปันผลต่อหุ้น

ตัวชี้วัด
แนวโน้ม 5 ปี
CVS
ค่ามัธยฐานของกลุ่มอุตสาหกรรม
EPS (Diluted) (EPS (ปรับลด))
5-point trend, -76.9%
$1.39

ประสิทธิภาพของเงินทุน อัตราหมุนเวียนสินทรัพย์, อัตราหมุนเวียนสินค้าคงคลัง, อัตราหมุนเวียนลูกหนี้

ตัวชี้วัด
แนวโน้ม 5 ปี
CVS
ค่ามัธยฐานของกลุ่มอุตสาหกรรม
Payout Ratio (อัตราการจ่ายเงินปันผล)
5-point trend, +478.9%
192.1%

เงินปันผล ผลตอบแทน, อัตราการจ่ายเงินปันผล, ประวัติเงินปันผล, CAGR 5 ปี

อัตราผลตอบแทนเงินปันผล
2.8%
อัตราการจ่ายเงินปันผล
192.1%
CAGR เงินปันผล 5 ปี
วันที่ไม่ได้รับสิทธิปันผลจำนวน
23 กรกฎาคม 2026$0.6650
23 เมษายน 2026$0.6650
22 มกราคม 2026$0.6650
23 ตุลาคม 2025$0.6650
22 กรกฎาคม 2025$0.6650
22 เมษายน 2025$0.6650
23 มกราคม 2025$0.6650
21 ตุลาคม 2024$0.6650
22 กรกฎาคม 2024$0.6650
19 เมษายน 2024$0.6650
19 มกราคม 2024$0.6650
19 ตุลาคม 2023$0.6050
20 กรกฎาคม 2023$0.6050
20 เมษายน 2023$0.6050
19 มกราคม 2023$0.6050
20 ตุลาคม 2022$0.5500
21 กรกฎาคม 2022$0.5500
21 เมษายน 2022$0.5500
20 มกราคม 2022$0.5500
21 ตุลาคม 2021$0.5000

CVS ความเห็นหลายต่อหลายของนักวิเคราะห์ มุมมองนักวิเคราะห์ทั้งเชิงบวกและเชิงลบ, ราคาเป้าหมาย 12 เดือน, อัพไซด์

ซื้อ 33 นักวิเคราะห์
  • ซื้อแนะนำ 8 24.2%
  • ซื้อ 20 60.6%
  • ถือ 5 15.2%
  • ขาย 0 0.0%
  • ขายแนะนำ 0 0.0%

ราคาเป้าหมาย 12 เดือน

25 นักวิเคราะห์ · 2026-08-17
ราคาเป้าหมายค่ามัธยฐาน $116.00 +22.8%
ราคาเป้าหมายค่าเฉลี่ย $116.08 +22.9%

ประวัติผลประกอบการ EPS จริงเทียบกับประมาณการ, เปอร์เซ็นต์ส่วนต่าง%, อัตราการชนะ, วันประกาศผลประกอบการครั้งถัดไป

ค่าเฉลี่ยส่วนต่าง
0.37%
งวด EPS Actual EPS คาด ส่วนต่าง
30 มิถุนายน 2026 $2.58 $1.87 0.71%
31 มีนาคม 2026 $2.57 $2.22 0.35%
31 ธันวาคม 2025 $1.09 $1.00 0.09%
30 กันยายน 2025 $1.60 $1.38 0.22%
30 มิถุนายน 2025 $1.81 $1.47 0.34%
31 มีนาคม 2025 $2.25 $1.72 0.53%

การเปรียบเทียบกับบริษัทคู่เทียบ (อุตสาหกรรมย่อย GICS) เมตริกสำคัญเทียบกับบริษัทในกลุ่มอุตสาหกรรมเดียวกัน

Ticker มูลค่าตลาด P/E รายได้ YoY อัตรากำไรสุทธิ ROE อัตรากำไรขั้นต้น
CVS $100.87B 57.1 7.8% 0.44% 2.4%
CI $72.51B 12.4 11.2% 2.2% 14.4%
DGX $19.09B 19.8 11.8% 9.0% 14.2%
LH $20.62B 24.0 7.2% 6.3% 10.3% 28.8%
GH $13.34B -30.8 32.9% -42.4% 205.7%
LH $20.62B 24.0 7.2% 6.3% 10.3% 28.8%
BTSG $7.20B 43.0 28.2% 1.5% 10.8% 11.8%
DVA $7.79B 11.5 6.5% 5.5% -281.8%
HNGE $0 -6.0 50.6% -89.9% -299.8% 79.7%
CHE 23.3 4.1% 10.5% 24.4%
HIMS 63.7 59.0% 5.5% 23.3% 73.8%

ปัจจัยพื้นฐานฉบับเต็ม ตัวชี้วัดทั้งหมดรายปี — งบกำไรขาดทุน, งบดุล, งบกระแสเงินสด

งบกำไรขาดทุน 16
ข้อมูล งบกำไรขาดทุน รายปีสำหรับ CVS
ตัวชี้วัด แนวโน้ม 20252024202320222021202020192018201720162015
Revenue 10-point trend, +162.3% $402.07B $372.81B $357.78B $322.47B $292.11B $268.71B $256.78B · $184.79B $177.55B $153.29B
Cost of Revenue 10-point trend, +74.5% $221.17B $206.29B $217.10B $196.89B $175.80B $163.98B $158.72B · $153.45B $146.53B $126.76B
Gross Profit 3-point trend, +7.6% · · · · · · · · $28.55B $28.86B $26.53B
Operating Expenses 10-point trend, +2230.4% $397.41B $364.29B $344.03B $314.51B $278.80B $254.79B $244.79B · $18.81B $18.45B $17.05B
Operating Income 10-point trend, -50.8% $4.66B $8.52B $13.74B $7.95B $13.31B $13.91B $11.99B · $9.54B $10.39B $9.47B
Interest Expense 8-point trend, +209.4% · · $2.66B $2.29B $2.50B $2.91B $3.04B · $1.06B $1.08B $859M
Interest Income 3-point trend, +0.0% · · · · · · · · $21M $20M $21M
Other Non-op 9-point trend, +500.0% $112M $99M $88M $169M $182M $206M $124M · $-208M $-28M ·
Pretax Income 10-point trend, -75.2% $2.14B $6.15B $11.17B $5.84B $10.54B $9.77B $9.00B · $8.27B $8.64B $8.62B
Income Tax 10-point trend, -88.0% $408M $1.56B $2.81B $1.51B $2.55B $2.57B $2.37B · $1.64B $3.32B $3.39B
Net Income 10-point trend, -66.2% $1.77B $4.61B $8.34B $4.31B $8.00B $7.18B $6.63B · $6.62B $5.32B $5.24B
EPS (Basic) 10-point trend, -70.0% $1.40 $3.67 $6.49 $3.29 $6.07 $5.48 $5.10 · $6.47 $4.93 $4.66
EPS (Diluted) 10-point trend, -70.0% $1.39 $3.66 $6.47 $3.26 $6.02 $5.46 $5.08 · $6.44 $4.90 $4.63
Shares (Basic) 10-point trend, +13.3% 1,267,000,000 1,259,000,000 1,285,000,000 1,312,000,000 1,319,000,000 1,309,000,000 1,301,000,000 · 1,020,000,000 1,073,000,000 1,118,000,000
Shares (Diluted) 10-point trend, +12.9% 1,271,000,000 1,262,000,000 1,290,000,000 1,323,000,000 1,329,000,000 1,314,000,000 1,305,000,000 · 1,024,000,000 1,079,000,000 1,126,000,000
EBITDA 10-point trend, -2.0% $9.27B $13.11B $18.11B $11.99B $17.70B $18.35B $16.36B · $12.00B $10.34B $9.45B
งบดุล 31
ข้อมูล งบดุล รายปีสำหรับ CVS
ตัวชี้วัด แนวโน้ม 20252024202320222021202020192018201720162015
Cash & Equivalents 10-point trend, +243.8% $8.45B $8.59B $8.20B $12.95B $9.41B $7.85B $5.68B · $1.70B $3.37B $2.46B
Short-term Investments 10-point trend, +2337.5% $2.15B $2.41B $3.26B $2.78B $3.12B $3.00B $2.37B · $111M $87M $88M
Receivables 10-point trend, +234.6% $39.78B $36.47B $35.23B $27.28B $24.43B $21.74B $19.62B · $13.18B $12.16B $11.89B
Inventory 10-point trend, +37.5% $19.25B $18.11B $18.02B $19.09B $17.76B $18.50B $17.52B · $15.30B $14.76B $14.00B
Other Current Assets 11-point trend, +605.1% $5.09B $3.08B $3.15B $2.64B $5.29B $5.28B $5.11B $4.53B $945M $660M $722M
Current Assets 11-point trend, +156.2% $74.71B $68.64B $67.86B $65.63B $60.01B $56.37B $50.30B $45.20B $31.23B $31.04B $29.16B
PP&E (Net) 8-point trend, +30.6% · · · $12.87B $12.90B $12.61B $12.04B $11.36B $10.29B $10.18B $9.86B
PP&E (Gross) 7-point trend, +64.5% · · · $34.60B $33.55B $31.31B $28.93B · $24.29B $22.80B $21.04B
Accum. Depreciation 7-point trend, +92.1% · · · $21.48B $20.65B $18.70B $16.89B · $14.00B $12.63B $11.18B
Goodwill 10-point trend, +124.3% $85.48B $91.27B $91.27B $78.15B $79.12B $79.55B $79.75B · $38.45B $38.25B $38.11B
Intangibles 11-point trend, +83.8% $25.51B $27.32B $29.23B $24.80B $29.03B $31.14B $33.12B $36.31B $13.63B $13.51B $13.88B
Other Non-current Assets 11-point trend, +394.0% $7.11B $4.79B $4.66B $4.62B $4.71B $4.62B $4.60B $4.53B $1.42B $1.49B $1.44B
Total Assets 11-point trend, +174.3% $253.54B $253.22B $249.73B $228.28B $233.00B $230.72B $222.45B $216.67B $95.13B $94.46B $92.44B
Accounts Payable 3-point trend, +18.3% · · · · · · · · $8.86B $7.95B $7.49B
Accrued Liabilities 11-point trend, +227.8% $22.39B $20.81B $23.52B $18.75B $17.67B $14.24B $12.13B $10.66B $6.58B $6.94B $6.83B
Short-term Debt 9-point trend, +0.00 $0 $2.12B $200M $0 · $0 $0 · $1.28B $1.87B $0
Current Liabilities 11-point trend, +282.8% $88.69B $84.61B $79.19B $69.42B $67.81B $62.02B $53.30B $45.76B $30.65B $26.25B $23.17B
Capital Leases 9-point trend, +4358.5% $13.64B $14.90B $16.03B $16.80B $18.18B $18.76B $18.93B $18.83B $306M · ·
Deferred Tax 11-point trend, -9.1% $3.83B $3.81B $4.31B $4.02B $6.27B $6.79B $7.29B $7.74B $3.00B $4.21B $4.22B
Other Non-current Liabilities 11-point trend, +339.1% $6.77B $5.43B $6.21B $6.73B $1.90B $2.35B $2.16B $2.26B $1.28B $1.55B $1.54B
Total Liabilities 9-point trend, +210.2% $178.16B $177.49B $173.09B $156.51B $157.62B $161.01B $158.28B $157.95B $57.44B · ·
Long-term Debt 5-point trend, +149.0% · · · · · · $68.48B $72.61B $27.00B $25.70B $27.50B
Total Debt 7-point trend, -100.0% $0 $2.12B $200M · · · $3.78B · $27.00B $27.53B $27.46B
Common Stock 9-point trend, +5.9% · $18M $18M $18M $17M $17M $17M · $17M $17M $17M
Paid-in Capital 3-point trend, +3.7% · · · · · · · · $32.08B $31.62B $30.95B
Retained Earnings 11-point trend, +72.4% $61.20B $62.84B $61.60B $56.40B $54.91B $49.64B $45.11B $41.09B $43.56B $38.98B $35.51B
Treasury Stock 10-point trend, +27.4% $36.79B $36.82B $33.84B $31.86B $28.17B $28.18B $28.23B · $37.80B $33.45B $28.89B
AOCI 10-point trend, +213.4% $406M $-120M $-297M $-1.26B $965M $1.41B $1.02B · $-165M $-305M $-358M
Stockholders' Equity 11-point trend, +102.2% $75.21B $75.56B $76.46B $71.47B $75.08B $69.39B $63.86B $58.40B $37.69B $36.83B $37.20B
Liabilities + Equity 10-point trend, +174.3% $253.54B $253.22B $249.73B $228.28B $233.00B $230.72B $222.45B · $95.13B $94.46B $92.44B
Shares Outstanding 10-point trend, +15.4% 1,271,000,000 1,260,000,000 1,288,000,000 1,300,000,000 1,322,000,000 1,310,000,000 1,302,000,000 · 1,712,000,000 1,061,000,000 1,101,000,000
กระแสเงินสด 19
ข้อมูล กระแสเงินสด รายปีสำหรับ CVS
ตัวชี้วัด แนวโน้ม 20252024202320222021202020192018201720162015
D&A 10-point trend, +120.2% $4.61B $4.60B $4.37B $4.22B $4.49B $4.44B $4.37B · $2.48B $2.48B $2.09B
Stock-based Comp 10-point trend, +132.6% $535M $540M $588M $447M $484M $400M $453M · $234M $222M $230M
Deferred Tax 10-point trend, +143.6% $102M $-572M $-676M $-2.03B $-402M $-564M $-649M · $-1.42B $3M $-234M
Amort. of Intangibles 10-point trend, +227.3% $2.00B $2.00B $1.90B $1.80B $2.20B $2.30B $2.40B · $817M $795M $611M
Restructuring · · · · · · · · $215M · ·
Other Non-cash 8-point trend, +3801.1% $3.63B $-72M $804M $9.41B $5.79B $4.41B $2.04B · $93M · ·
Operating Cash Flow 10-point trend, +24.6% $10.64B $9.11B $13.43B $16.18B $18.27B $15.87B $12.85B · $8.01B $10.14B $8.54B
CapEx 10-point trend, +19.6% $2.83B $2.78B $3.03B $2.73B $2.52B $2.44B $2.46B · $1.92B $2.22B $2.37B
Investing Cash Flow 10-point trend, +56.3% $-5.87B $-7.61B $-20.89B $-5.05B $-5.26B $-5.53B $-3.34B · $-2.88B $-2.47B $-13.42B
Debt Issued 10-point trend, -73.2% $3.97B $7.91B $10.90B $0 $987M $9.96B $3.74B · $0 $3.46B $14.80B
Net Debt Issued 9-point trend, -97.1% $340M $3.14B $7.73B $-4.21B $-9.27B $-5.67B $-4.60B · · $-2.49B $11.90B
Stock Repurchased 10-point trend, -100.0% $0 $3.02B $2.01B $3.50B $0 $0 $0 · $4.36B $4.46B $5.00B
Net Stock Activity 8-point trend, +100.0% $0 $-3.02B $-2.01B $-3.50B · · $0 · $-4.36B $-4.46B $-5.00B
Dividends Paid 10-point trend, +115.5% $3.40B $3.37B $3.13B $2.91B $2.62B $2.62B $2.60B · $2.05B $1.84B $1.58B
Financing Cash Flow 10-point trend, -201.3% $-4.94B $-1.14B $2.68B $-10.52B $-11.36B $-7.70B $-7.65B · $-6.75B $-6.76B $4.88B
Net Change in Cash 10-point trend, -681.8% $-172M $359M $-4.78B $614M $1.65B $2.63B $1.85B · $-1.62B $912M $-22M
Taxes Paid 10-point trend, -33.8% $2.17B $1.70B $3.52B $4.12B $3.19B $2.93B $2.72B · $2.91B $3.06B $3.27B
Free Cash Flow 10-point trend, +29.1% $7.81B $6.33B $10.39B $13.45B $15.74B $13.43B $10.39B · $6.09B $7.84B $6.04B
Levered FCF 8-point trend, +52.2% · · $8.40B $11.76B $13.85B $11.29B $8.15B · $5.24B $7.18B $5.52B
ความสามารถในการทำกำไร 8
ข้อมูล ความสามารถในการทำกำไร รายปีสำหรับ CVS
ตัวชี้วัด แนวโน้ม 20252024202320222021202020192018201720162015
Gross Margin 3-point trend, -10.7% · · · · · · · · 15.4% 16.3% 17.3%
Operating Margin 10-point trend, -81.2% 1.2% 2.3% 3.8% 2.4% 4.5% 5.2% 4.7% · 5.1% 5.8% 6.2%
Net Margin 10-point trend, -87.1% 0.44% 1.2% 2.3% 1.3% 2.7% 2.7% 2.6% · 3.6% 3.0% 3.4%
Pretax Margin 10-point trend, -90.6% 0.53% 1.7% 3.1% 1.8% 3.6% 3.6% 3.5% · 4.5% 4.9% 5.6%
EBITDA Margin 10-point trend, -62.7% 2.3% 3.5% 5.1% 3.7% 6.1% 6.8% 6.4% · 6.5% 5.8% 6.2%
ROA 10-point trend, -88.8% 0.70% 1.8% 3.5% 1.8% 3.4% 3.2% 3.0% · 7.0% 5.7% 6.2%
ROE 10-point trend, -83.1% 2.4% 6.1% 11.3% 5.7% 10.9% 10.8% 10.8% · 17.8% 14.4% 13.9%
ROIC 10-point trend, -43.6% 5.0% 8.2% 13.4% 8.1% 13.3% 14.8% 13.1% · 11.8% 9.9% 8.9%
สภาพคล่องและความสามารถในการชำระหนี้ 5
ข้อมูล สภาพคล่องและความสามารถในการชำระหนี้ รายปีสำหรับ CVS
ตัวชี้วัด แนวโน้ม 20252024202320222021202020192018201720162015
Current Ratio 10-point trend, -35.7% 0.8 0.8 0.9 0.9 0.9 0.9 0.9 · 1.0 1.2 1.3
Quick Ratio 10-point trend, -8.8% 0.6 0.6 0.6 0.6 0.5 0.5 0.5 · 0.5 0.6 0.6
Debt / Equity 7-point trend, -100.0% 0.0 0.0 0.0 · · · 0.1 · 0.7 0.7 0.7
LT Debt / Equity 3-point trend, -16.7% · · · · · · · · 0.6 0.7 0.7
Interest Coverage 8-point trend, -53.0% · · 5.2 3.4 5.3 4.8 3.9 · 9.0 9.6 11.0
ประสิทธิภาพ 3
ข้อมูล ประสิทธิภาพ รายปีสำหรับ CVS
ตัวชี้วัด แนวโน้ม 20252024202320222021202020192018201720162015
Asset Turnover 10-point trend, -13.1% 1.6 1.5 1.5 1.4 1.3 1.2 1.2 · 1.9 1.9 1.8
Inventory Turnover 10-point trend, +21.1% 11.8 11.4 11.7 10.7 9.7 9.1 9.3 · 10.4 10.3 9.8
Receivables Turnover 10-point trend, -25.8% 10.5 10.4 11.4 12.5 12.7 13.0 13.8 · 14.6 14.8 14.2
ต่อหุ้น 7
ข้อมูล ต่อหุ้น รายปีสำหรับ CVS
ตัวชี้วัด แนวโน้ม 20252024202320222021202020192018201720162015
Book Value / Share 10-point trend, +75.2% $59.18 $59.97 $59.36 $54.63 $56.79 $52.97 $49.05 · $37.17 $34.71 $33.78
Revenue / Share 10-point trend, +132.4% $316.34 $295.41 $277.35 $243.74 $219.80 $204.49 $196.76 · $180.43 $164.53 $136.14
Cash Flow / Share 10-point trend, +12.0% $8.37 $7.22 $10.41 $12.23 $13.74 $12.07 $9.85 · $7.82 $9.33 $7.47
Cash / Share 10-point trend, +197.8% $6.65 $6.81 $6.36 $9.96 $7.12 $6.00 $4.36 · $1.67 $3.18 $2.23
Dividend / Share 10-point trend, +90.0% $3 $3 $2 $2 $2 $2 $2 · $2 $2 $1
Dividend Paid / Share · · · · · · · · $2 · ·
EPS (TTM) 10-point trend, -70.0% $1.39 $3.66 $6.47 $3.26 $6.02 $5.46 $5.08 · $6.44 $4.90 $4.63
อัตราการเติบโต 10
ข้อมูล อัตราการเติบโต รายปีสำหรับ CVS
ตัวชี้วัด แนวโน้ม 20252024202320222021202020192018201720162015
Revenue YoY 5-point trend, -9.9% 7.8% 4.2% 10.9% 10.4% 8.7% · · · · · ·
Revenue CAGR 3Y 3-point trend, -23.8% 7.6% 8.5% 10.0% · · · · · · · ·
Revenue CAGR 5Y 8.4% · · · · · · · · · ·
EPS YoY 5-point trend, -704.5% -62.0% -43.4% 98.5% -45.9% 10.3% · · · · · ·
EPS CAGR 3Y 3-point trend, -524.9% -24.7% -15.3% 5.8% · · · · · · · ·
EPS CAGR 5Y -23.9% · · · · · · · · · ·
Net Income YoY 5-point trend, -638.7% -61.7% -44.7% 93.5% -46.1% 11.5% · · · · · ·
Net Income CAGR 3Y 3-point trend, -600.0% -25.7% -16.8% 5.1% · · · · · · · ·
Net Income CAGR 5Y -24.4% · · · · · · · · · ·
Dividend CAGR 5Y 5.3% · · · · · · · · · ·
การประเมินมูลค่า (TTM) 16
ข้อมูล การประเมินมูลค่า (TTM) รายปีสำหรับ CVS
ตัวชี้วัด แนวโน้ม 20252024202320222021202020192018201720162015
Revenue TTM 10-point trend, +162.3% $402.07B $372.81B $357.78B $322.47B $292.11B $268.71B $256.78B · $184.79B $177.55B $153.29B
Net Income TTM 10-point trend, -66.2% $1.77B $4.61B $8.34B $4.31B $8.00B $7.18B $6.63B · $6.62B $5.32B $5.24B
Market Cap 10-point trend, -6.3% $100.87B $56.56B $101.70B $121.15B $136.38B $89.47B $96.73B · $73.52B $83.72B $107.64B
Enterprise Value 7-point trend, -31.9% $90.27B $47.69B $90.45B · · · $92.45B · $98.71B $107.80B $132.56B
P/E 10-point trend, +170.4% 57.1 12.3 12.2 28.6 17.1 12.5 14.6 · 11.3 16.1 21.1
P/S 10-point trend, -64.3% 0.3 0.2 0.3 0.4 0.5 0.3 0.4 · 0.4 0.5 0.7
P/B 10-point trend, -53.7% 1.3 0.7 1.3 1.7 1.8 1.3 1.5 · 2.0 2.3 2.9
P / Cash Flow 10-point trend, -25.9% 9.5 6.2 7.6 7.5 7.5 5.6 7.5 · 9.2 8.3 12.8
P / FCF 10-point trend, -27.4% 12.9 8.9 9.8 9.0 8.7 6.7 9.3 · 12.1 10.7 17.8
EV / EBITDA 7-point trend, -30.5% 9.7 3.6 5.0 · · · 5.7 · 8.2 10.4 14.0
EV / FCF 7-point trend, -47.3% 11.6 7.5 8.7 · · · 8.9 · 16.2 13.7 21.9
EV / Revenue 7-point trend, -74.0% 0.2 0.1 0.3 · · · 0.4 · 0.5 0.6 0.9
Dividend Yield 10-point trend, +130.8% 3.4% 6.0% 3.1% 2.4% 1.9% 2.9% 2.7% · 2.8% 2.2% 1.5%
Earnings Yield 10-point trend, -63.1% 1.8% 8.2% 8.2% 3.5% 5.8% 8.0% 6.8% · 8.9% 6.2% 4.7%
Payout Ratio 10-point trend, +538.8% 192.1% 73.1% 37.5% 70.1% 33.2% 36.5% 39.2% · 30.9% 34.6% 30.1%
Annual Payout 10-point trend, +115.5% $3.40B $3.37B $3.13B $2.91B $2.62B $2.62B $2.60B · $2.05B $1.84B $1.58B

งบการเงิน งบกำไรขาดทุน, งบดุล, งบกระแสเงินสด — รายปี, 5 ปีล่าสุด

งบกำไรขาดทุน
2025-12-312024-12-312023-12-312022-12-312021-12-31
รายได้ $402.07B$372.81B$357.78B$322.47B$292.11B
อัตรากำไรจากการดำเนินงาน % 1.2%2.3%3.8%2.4%4.5%
กำไรสุทธิ $1.77B$4.61B$8.34B$4.31B$8.00B
EPS ที่ปรับลดแล้ว $1.39$3.66$6.47$3.26$6.02
งบดุล
2025-12-312024-12-312023-12-312022-12-312021-12-31
หนี้สินต่อทุน 0.00.00.0
อัตราส่วนสภาพคล่อง 0.80.80.90.90.9
อัตราส่วนเงินสด 0.60.60.60.60.5
กระแสเงินสด
2025-12-312024-12-312023-12-312022-12-312021-12-31
กระแสเงินสดอิสระ $7.81B$6.33B$10.39B$13.45B$15.74B

ข่าวล่าสุด หัวข้อข่าวล่าสุดที่กล่าวถึงบริษัทนี้

สัญญาณซื้อขาย สัญญาณซื้อ/ขายล่าสุดพร้อมราคาเข้าและอัตราส่วนความเสี่ยง/ผลตอบแทน

ตัวชี้วัดของฉัน รายการเฝ้าดูส่วนตัวของคุณ — แถวที่เลือกจากข้อมูลพื้นฐานฉบับเต็ม

📊

เลือกเมตริกที่สำคัญสำหรับคุณ — คลิก ➕ ถัดจากแถวใดก็ได้ในข้อมูลพื้นฐานฉบับเต็มด้านบน

การเลือกของคุณถูกบันทึกและจะติดตามคุณไปในทุกสัญลักษณ์หุ้น

ผู้ถือครองสถาบัน (13F) 2,290 รายงาน · $77.0B ทั้งหมด · ณ วันที่ 30 มิถุนายน 2026

สถาบันที่รายงานการถือครองหุ้นนี้ในเอกสาร SEC Form 13F รายไตรมาสของตน เฉพาะสถานะ Long; ผู้ยื่นคำร้องรายเดียวอาจปรากฏสองครั้งสำหรับสัญญาออปชันที่แยกจากกัน ขา put/call ขนาดใหญ่ที่หักล้างกันมักสะท้อนถึงการทำตลาด (market-making) หรือสินค้าคงคลังที่มีการป้องกันความเสี่ยง (hedged inventory) ไม่ใช่การเชื่อมั่นในทิศทาง

กิจกรรมของผู้ลงทุนสถาบัน — Q2 2026 เทียบกับไตรมาสก่อนหน้า
พอร์ตใหม่ ตำแหน่งที่ปิดไปแล้ว เพิ่มขึ้น ลดลง การเปลี่ยนแปลงสุทธิของจำนวนหุ้น
319 (+131 เทียบกับไตรมาสก่อน) 93 (-97 เทียบกับไตรมาสก่อน) 783 (+85 เทียบกับไตรมาสก่อน) 714 (-58 เทียบกับไตรมาสก่อน) +184.0M

เปรียบเทียบกับ Q1 2026. การยื่นแบบฟอร์ม 13F ของ SEC จะครบกำหนดภายใน 45 วันนับจากสิ้นสุดไตรมาส บวกกับระยะเวลาผ่อนผันสั้นๆ สำหรับผู้ยื่นล่าช้า — ไตรมาสที่ยังอยู่ในช่วงเวลานี้จะถูกข้ามไปเพื่อใช้คู่ที่รายงานล่าสุดอย่างสมบูรณ์

สถาบัน มูลค่า หุ้น % ของ 13F ที่ติดตาม ประเภท
VANGUARD CAPITAL MANAGEMENT LLC $8,618,974,924 83,315,369 11.20% หุ้น
Capital World Investors $7,753,834,783 74,951,955 10.08% หุ้น
STATE STREET CORP $6,236,318,558 60,283,408 8.10% หุ้น
Dodge & Cox $5,173,820,539 50,012,765 6.72% หุ้น
WELLINGTON MANAGEMENT GROUP LLP $3,266,370,439 31,574,388 4.24% หุ้น
VANGUARD PORTFOLIO MANAGEMENT LLC $2,755,624,444 26,637,259 3.58% หุ้น
GEODE CAPITAL MANAGEMENT, LLC $2,646,473,316 25,714,722 3.44% หุ้น
Capital Research Global Investors $2,516,851,376 24,329,151 3.27% หุ้น
NORGES BANK $1,866,126,481 18,038,922 2.42% หุ้น
FMR LLC $1,684,924,609 16,287,333 2.19% หุ้น
Capital International Investors $1,591,868,430 15,387,600 2.07% หุ้น
Davis Selected Advisers $1,227,594,458 11,865,916 1.60% หุ้น
Clearbridge Investments, LLC $878,119,687 8,488,349 1.14% หุ้น
GQG Partners LLC $822,989,370 7,955,411 1.07% หุ้น
AMERIPRISE FINANCIAL INC $761,355,564 7,357,966 0.99% หุ้น
VANGUARD FIDUCIARY TRUST CO $741,242,940 7,165,229 0.96% หุ้น
DIMENSIONAL FUND ADVISORS LP $643,180,166 6,217,304 0.84% หุ้น
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $524,415,257 5,069,263 0.68% หุ้น
GLENVIEW CAPITAL MANAGEMENT, LLC $499,125,457 4,824,799 0.65% หุ้น
CITADEL ADVISORS LLC $493,765,609 4,772,988 0.64% หุ้น
VIKING GLOBAL INVESTORS LP $378,974,695 3,663,361 0.49% หุ้น
Swiss National Bank $371,195,152 3,588,160 0.48% หุ้น
BlackRock, Inc. $364,982,048 3,528,101 0.47% หุ้น
RAYMOND JAMES FINANCIAL INC $354,997,941 3,431,590 0.46% หุ้น
National Pension Service $352,166,145 3,404,216 0.46% หุ้น
ROYAL BANK OF CANADA $338,495,000 3,272,060 0.44% หุ้น
Mitsubishi UFJ Asset Management Co., Ltd. $322,653,390 3,118,927 0.42% หุ้น
GOLDMAN SACHS GROUP INC $319,964,422 3,092,938 0.42% หุ้น
Legal & General Group Plc $315,302,980 3,047,878 0.41% หุ้น
Holocene Advisors, LP $310,524,210 3,001,684 0.40% หุ้น
ENVESTNET ASSET MANAGEMENT INC $300,309,006 2,902,944 0.39% หุ้น
CITADEL ADVISORS LLC $299,591,200 2,896,000 0.39% สัญญาซื้อล่วงหน้า
Sumitomo Mitsui Trust Group, Inc. $298,855,050 2,888,884 0.39% หุ้น
Vanguard Global Advisers, LLC $295,578,375 2,857,210 0.38% หุ้น
VANGUARD ASSET MANAGEMENT, Ltd $295,497,373 2,856,427 0.38% หุ้น
FAIRFAX FINANCIAL HOLDINGS LTD/ CAN $280,502,160 2,712,000 0.36% หุ้น
CITADEL ADVISORS LLC $267,076,865 2,581,700 0.35% สัญญาขายล่วงหน้า
BNP PARIBAS FINANCIAL MARKETS $261,748,880 2,530,197 0.34% หุ้น
BANK OF AMERICA CORP /DE/ $249,417,276 2,410,993 0.32% หุ้น
PRIMECAP MANAGEMENT CO/CA/ $246,778,944 2,385,490 0.32% หุ้น
RHUMBLINE ADVISERS $246,744,475 2,385,158 0.32% หุ้น
FRANKLIN RESOURCES INC $238,592,528 2,306,356 0.31% หุ้น
California Public Employees Retirement System $233,879,967 2,260,802 0.30% หุ้น
ALLIANCEBERNSTEIN L.P. $232,194,060 3,233,000 0.30% หุ้น
JANE STREET GROUP, LLC $231,055,575 2,233,500 0.30% สัญญาขายล่วงหน้า
CANADA PENSION PLAN INVESTMENT BOARD $230,615,292 2,229,244 0.30% หุ้น
Canoe Financial LP $226,952,024 2,193,833 0.29% หุ้น
MILLENNIUM MANAGEMENT LLC $223,951,974 2,164,833 0.29% หุ้น
VANGUARD GROUP INC $222,935,255 2,809,164 0.29% หุ้น
UBS Group AG $221,527,830 2,141,400 0.29% สัญญาซื้อล่วงหน้า
Brandywine Global Investment Management, LLC $216,103,153 2,723,074 0.28% หุ้น
Robeco Institutional Asset Management B.V. $207,806,227 2,008,760 0.27% หุ้น
Zurcher Kantonalbank (Zurich Cantonalbank) $205,293,939 1,984,475 0.27% หุ้น
Point72 Asset Management, L.P. $202,868,760 1,961,032 0.26% หุ้น
JANUS HENDERSON GROUP PLC $200,732,734 2,794,942 0.26% หุ้น
JANE STREET GROUP, LLC $190,306,620 1,839,600 0.25% สัญญาซื้อล่วงหน้า
JONES FINANCIAL COMPANIES LLLP $186,577,346 1,788,167 0.24% หุ้น
Assenagon Asset Management S.A. $183,757,718 1,776,295 0.24% หุ้น
MACKENZIE FINANCIAL CORP $177,786,480 1,718,574 0.23% หุ้น
Hamlin Capital Management, LLC $177,686,548 1,717,608 0.23% หุ้น
Alyeska Investment Group, L.P. $174,358,768 1,685,440 0.23% หุ้น
ADAGE CAPITAL PARTNERS GP, L.L.C. $169,576,171 1,639,209 0.22% หุ้น
LPL Financial LLC $160,912,185 1,555,458 0.21% หุ้น
PRUDENTIAL FINANCIAL INC $156,319,985 1,511,068 0.20% หุ้น
GOLDMAN SACHS GROUP INC $153,033,585 1,479,300 0.20% สัญญาซื้อล่วงหน้า
Quantinno Capital Management LP $150,197,267 1,451,882 0.20% หุ้น
PRINCIPAL FINANCIAL GROUP INC $149,812,359 1,448,162 0.19% หุ้น
NEW YORK STATE COMMON RETIREMENT FUND $146,277,266 1,413,990 0.19% หุ้น
VICTORY CAPITAL MANAGEMENT INC $143,800,879 1,390,052 0.19% หุ้น
PANAGORA ASSET MANAGEMENT INC $143,310,113 1,385,308 0.19% หุ้น
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $135,669,704 1,889,024 0.18% หุ้น
MANUFACTURERS LIFE INSURANCE COMPANY, THE $133,185,771 1,287,441 0.17% หุ้น
BARCLAYS PLC $130,962,631 1,265,951 0.17% หุ้น
UBS Group AG $130,742,593 1,263,824 0.17% หุ้น
MACQUARIE GROUP LTD $130,222,860 1,258,800 0.17% หุ้น
Patient Capital Management, LLC $127,813,106 1,235,505 0.17% หุ้น
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. $125,407,000 1,212,248 0.16% หุ้น
Maple Rock Capital Partners Inc. $123,932,686 1,197,996 0.16% หุ้น
BANK OF MONTREAL /CAN/ $120,915,774 1,168,833 0.16% หุ้น
Qube Research & Technologies Ltd $118,745,083 1,147,850 0.15% หุ้น
TD Asset Management Inc $117,174,298 1,132,666 0.15% หุ้น
SCHRODER INVESTMENT MANAGEMENT GROUP $114,781,970 1,108,148 0.15% หุ้น
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND $114,360,975 1,105,471 0.15% หุ้น
AVIVA PLC $113,872,588 1,100,750 0.15% หุ้น
Integral Health Asset Management, LLC $113,795,000 1,100,000 0.15% หุ้น
LETKO, BROSSEAU & ASSOCIATES INC $113,305,164 1,095,265 0.15% หุ้น
TRUIST FINANCIAL CORP $112,799,640 1,090,378 0.15% หุ้น
Woodline Partners LP $112,125,214 1,083,859 0.15% หุ้น
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM $111,580,653 1,078,595 0.14% หุ้น
STOREBRAND ASSET MANAGEMENT AS $111,494,582 1,077,763 0.14% หุ้น
NORDEA INVESTMENT MANAGEMENT AB $110,986,994 1,076,081 0.14% หุ้น
BANK OF NOVA SCOTIA $103,790,874 1,003,295 0.13% หุ้น
Capital International, Inc./CA/ $102,952,716 995,193 0.13% หุ้น
Universal- Beteiligungs- und Servicegesellschaft mbH $100,146,711 970,080 0.13% หุ้น
Walleye Trading LLC $98,691,300 954,000 0.13% สัญญาซื้อล่วงหน้า
Walleye Trading LLC $98,049,910 947,800 0.13% สัญญาขายล่วงหน้า
Korea Investment CORP $97,590,385 943,358 0.13% หุ้น
JENNISON ASSOCIATES LLC $97,539,798 942,869 0.13% หุ้น
SEB Asset Management AB $96,760,081 935,333 0.13% หุ้น
WORLDQUANT MILLENNIUM ADVISORS LLC $91,910,670 888,455 0.12% หุ้น

ผู้บริหารบริษัท 86 รายชื่อผู้บริหาร · ผู้บริหาร 48 คน · กรรมการ 41 คน

ผู้บริหารภายใน บทบาท กิจกรรมล่าสุด หุ้นที่ถือครอง ซื้อ 12 เดือน ขาย 12 เดือน สุทธิ 12 เดือน
David J. Joyner President, CEO and Chair 1 เมษายน 2026 F 70,349 0 0 $0
Karen S Lynch President and CEO 1 เมษายน 2024 A 74,687 0 0 $0
Brian Newman EVP, Chief Financial Officer 31 พฤษภาคม 2026 F 3,008 0 0 $0
Thomas F. Cowhey EVP and CFO 1 เมษายน 2025 A 41,109 0 0 $0
Shawn M Guertin EVP & Chief Financial Officer 1 เมษายน 2023 A 34,706 0 0 $0
Eva C Boratto EVP & CFO 4 พฤษภาคม 2021 S 115,331 0 0 $0
David M Denton EVP and CFO 29 พฤศจิกายน 2018 S 403 0 0 $0
David B Rickard Chief Financial Officer 14 ธันวาคม 2009 M 207,179 0 0 $0
Howard A Mclure President, Caremark Pharm Serv 2 พฤศจิกายน 2009 M 0 0 0 $0
Jonathan C Roberts EVP & Chief Operating Officer 1 เมษายน 2022 A 426,025 0 0 $0
James David Clark SVP, Cont & Chief Acct Officer 26 มิถุนายน 2026 F 27,606 0 0 $0
Amy Compton-Phillips EVP, Chief Medical Officer 31 พฤษภาคม 2026 F 9,557 0 0 $0
Tilak Mandadi EVP, Chief Exp & Tech Officer 8 พฤษภาคม 2026 S 10,133 0 1 $-6,230,379
Prem S Shah EVP and Group President 31 มีนาคม 2026 A 64,356 0 0 $0
Heidi B Capozzi EVP and Chief People Officer 31 มีนาคม 2026 A 13,023 3 0 $4,588
Samrat S. Khichi EVP, CPO and General Counsel 31 มีนาคม 2026 A 33,421 0 0 $0
Steven H Nelson EVP and President, Aetna 31 มีนาคม 2026 A 2,900 1 0 $1,289
Sreekanth K Chaguturu EVP and Chief Medical Officer 1 เมษายน 2024 A 23,666 0 0 $0
Laurie P. Havanec EVP and Chief People Officer 1 เมษายน 2024 A 9,426 0 0 $0
Brian A Kane EVP/President, Aetna 1 เมษายน 2024 A 12,569 0 0 $0
Finke Daniel P EVP/Pres, Health Care Benefits 1 เมษายน 2023 A 35,068 0 0 $0
Michelle A Peluso EVP and Co-President of Retail 1 เมษายน 2023 A 124,383 0 0 $0
Thomas M Moriarty EVP & General Counsel 31 ธันวาคม 2022 F 315,273 0 0 $0
Alan Lotvin EVP&President-PharmacyServices 4 สิงหาคม 2022 M 109,183 0 0 $0
Troyen A Brennan EVP and Chief Medical Officer 3 เมษายน 2022 F 232,676 0 0 $0
Neela Montgomery EVP and Pres., Pharmacy/Retail 1 เมษายน 2021 A 29,502 0 0 $0
Lisa Bisaccia Former EVP & Chief HR Officer 1 เมษายน 2021 F 66,417 0 0 $0
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL 28 กุมภาพันธ์ 2021 F 25,657 0 0 $0
Jonathan E. Mayhew EVP - Transformation 2 ธันวาคม 2020 F 6,855 0 0 $0
Derica W Rice EVP & President, CVS Caremark 28 กุมภาพันธ์ 2020 F 26,827 0 0 $0
Kevin Hourican EVP & President, CVS Pharmacy 1 เมษายน 2019 A 15,237 0 0 $0
Helena Foulkes EVP & President-CVS Pharmacy 16 กุมภาพันธ์ 2018 M 45,107 0 0 $0
Robert O. Kraft EVP and President - Omnicare 3 เมษายน 2017 A 92,360 0 0 $0
Andrew Sussman EVP, Clinical Services 3 เมษายน 2017 A 16,433 0 0 $0
Stephen J Gold EVP & CIO 3 เมษายน 2017 A 46,818 0 0 $0
Per Gh Lofberg EVP 2 มกราคม 2015 M 23,419 0 0 $0
Mark Cosby EVP & President-CVS/pharmacy 30 กันยายน 2013 M 45,955 0 0 $0
Laird Daniels SVP, Cont & Chief Acct Officer 1 เมษายน 2013 A 17,845 0 0 $0
Douglas A Sgarro EVP and CLO 11 พฤษภาคม 2012 M 214 0 0 $0
Stuart M Mcguigan SVP and CIO 16 มีนาคม 2012 M 10,967 0 0 $0
Thomas M Ryan Non-Executive Chairman 3 เมษายน 2011 F 1,156,702 0 0 $0
Sara Finley SVP, Gen Counsel 18 กุมภาพันธ์ 2011 F 29,053 0 0 $0
Michael V Ferdinandi Senior Vice President 19 สิงหาคม 2009 S 16,021 0 0 $0
Paula A Price Controller 12 กุมภาพันธ์ 2008 A 16,498 0 0 $0
Edwin M Crawford Chairman 29 ตุลาคม 2007 A 135,572 0 0 $0
William R Spalding EVP Caremark Pharmacy Services 18 มิถุนายน 2007 M 182 0 0 $0
Gregory S Weishar Vice President 3 เมษายน 2006 A 30,161 0 0 $0
Larry D Solberg Senior Vice President 16 กุมภาพันธ์ 2006 A 5,978 0 0 $0
ROBBINS LARRY กรรมการ 21 พฤษภาคม 2026 S 4,824,799 0 8 $-352,750,556
Fernando Aguirre กรรมการ 21 พฤษภาคม 2026 D 10,513 0 0 $0

ผู้บริหารจากเอกสาร SEC Form 3/4/5; สุทธิ = เฉพาะการซื้อขายในตลาดเปิด

นักเคลื่อนไหวและเจ้าของ %+ 5 1 รายการ

นักลงทุนที่ยื่น SEC Schedule 13D — กรรมสิทธิ์ตามผลประโยชน์ที่แท้จริงสูงกว่า % 5 โดยมีเจตนาที่จะมีอิทธิพลต่อผู้ออกหลักทรัพย์ (การถือหุ้นของนักเคลื่อนไหว, การรณรงค์ในคณะกรรมการ, M&A) แต่ละแถวแสดงสถานะล่าสุดที่ทราบของตำแหน่งของผู้ยื่นคำร้องรายนั้น

ผู้ยื่นคำร้อง ยื่นแล้ว ส่วนได้เสีย สถานะ วัตถุประสงค์ การยื่นคำร้อง
CVS Caremark Corporation 7 มกราคม 2011 การยื่นคำร้องครั้งแรก M&A / การขาย SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

การถือครอง ETF ถือโดย ETF 218 ราย

น้ำหนักสะท้อนถึงการถือครองหุ้นโดยตรง (N-PORT) เท่านั้น กองทุนเลเวอเรจหรือกองทุนที่อิงตราสารอนุพันธ์อาจมีการเปิดรับความเสี่ยงจากสัญญาแลกเปลี่ยน (swap) เพิ่มเติมซึ่งไม่แสดง

กองทุน น้ำหนัก หน่วย ณ วันที่ แหล่งที่มา
IHF · iShares Trust 13.66% 1,756,753 SH 8 สิงหาคม 2026 รายวัน
ROPE · EA Series Trust 5.27% 4,922 NS 29 พฤษภาคม 2026 N-PORT
DUSA · Davis Fundamental ETF Trust 4.57% 636,042 NS 30 เมษายน 2026 N-PORT
IYK · iShares Trust 4.22% 624,816 SH 8 สิงหาคม 2026 รายวัน
GEND · Spinnaker ETF Series 3.66% 1,968 NS 30 เมษายน 2026 N-PORT
PEZ · Invesco Exchange-Traded Fund Trust 3.42% 8,210 SH 8 สิงหาคม 2026 รายวัน
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 2.71% 3,618 NS 30 เมษายน 2026 N-PORT
ESN · Northern Lights Fund Trust II 2.58% 79,142 NS 31 พฤษภาคม 2026 N-PORT
DWLD · Davis Fundamental ETF Trust 2.33% 158,312 NS 30 เมษายน 2026 N-PORT
SDOG · ALPS ETF Trust 2.25% 342,879 NS 31 พฤษภาคม 2026 N-PORT
COWZ · Pacer Funds Trust 2.16% 4,706,232 NS 30 เมษายน 2026 N-PORT
QQWZ · Pacer Funds Trust 2.15% 12,078 NS 30 เมษายน 2026 N-PORT
RWL · Invesco Exchange-Traded Fund Trust … 1.95% 2,024,890 SH 8 สิงหาคม 2026 รายวัน
VHT · VANGUARD WORLD FUND 1.94% 3,824,297 SH 8 สิงหาคม 2026 รายวัน
FXG · First Trust Exchange-Traded AlphaDE… 1.89% 55,579 NS 30 เมษายน 2026 N-PORT
RPV · Invesco Exchange-Traded Fund Trust 1.88% 334,242 SH 8 สิงหาคม 2026 รายวัน
SPDV · ETF Series Solutions 1.86% 20,100 NS 30 เมษายน 2026 N-PORT
FHLC · FIDELITY COVINGTON TRUST 1.71% 585,200 NS 30 เมษายน 2026 N-PORT
RXL · ProShares Trust 1.67% 13,266 NS 31 พฤษภาคม 2026 N-PORT
IXJ · iShares Trust 1.55% 670,400 SH 8 สิงหาคม 2026 รายวัน
REVS · Columbia ETF Trust I 1.55% 52,621 NS 30 เมษายน 2026 N-PORT
CURE · Direxion Shares ETF Trust 1.53% 25,368 NS 30 เมษายน 2026 N-PORT
RSPH · Invesco Exchange-Traded Fund Trust 1.48% 120,955 SH 8 สิงหาคม 2026 รายวัน
SPVM · Invesco Exchange-Traded Fund Trust 1.45% 19,889 SH 8 สิงหาคม 2026 รายวัน
PWV · Invesco Exchange-Traded Fund Trust 1.40% 261,212 SH 8 สิงหาคม 2026 รายวัน
VLUE · iShares Trust 1.38% 1,353,743 SH 8 สิงหาคม 2026 รายวัน
DVY · iShares Trust 1.37% 3,341,969 SH 8 สิงหาคม 2026 รายวัน
ITAN · EA Series Trust 1.36% 13,295 NS 29 พฤษภาคม 2026 N-PORT
GKAT · Advisors Series Trust 1.30% 27,039 NS 31 มีนาคม 2026 N-PORT
GMOV · GMO ETF Trust 1.21% 12,118 NS 31 พฤษภาคม 2026 N-PORT
BSCS · Invesco Exchange-Traded Self-Indexe… 1.17% 41,394,000 8 สิงหาคม 2026 รายวัน
GURU · Global X Funds 1.17% 8,187 NS 30 เมษายน 2026 N-PORT
SPVU · Invesco Exchange-Traded Fund Trust … 1.13% 16,706 NS 31 พฤษภาคม 2026 N-PORT
SPXD · DBX ETF Trust 1.12% 830 NS 31 พฤษภาคม 2026 N-PORT
VRP · Invesco Exchange-Traded Fund Trust … 1.11% 31,567,000 8 สิงหาคม 2026 รายวัน
CVAR · ETF Opportunities Trust 1.01% 4,716 NS 30 เมษายน 2026 N-PORT
VCEB · VANGUARD WORLD FUND 0.99% 12,250,700 PA 8 สิงหาคม 2026 รายวัน
CGCV · Capital Group Conservative Equity E… 0.99% 189,872 NS 31 พฤษภาคม 2026 N-PORT
PALC · Pacer Funds Trust 0.98% 27,132 NS 30 เมษายน 2026 N-PORT
ABCS · EA Series Trust 0.98% 1,219 NS 29 พฤษภาคม 2026 N-PORT
FFLV · FIDELITY COVINGTON TRUST 0.97% 2,025 NS 30 เมษายน 2026 N-PORT
VFVA · VANGUARD WELLINGTON FUND 0.95% 77,895 SH 8 สิงหาคม 2026 รายวัน
EQWL · Invesco Exchange-Traded Fund Trust 0.92% 267,202 SH 8 สิงหาคม 2026 รายวัน
FNDX · SCHWAB STRATEGIC TRUST 0.91% 2,553,383 NS 31 พฤษภาคม 2026 N-PORT
VCLT · VANGUARD SCOTTSDALE FUNDS 0.91% 98,192,000 PA 8 สิงหาคม 2026 รายวัน
IUS · Invesco Exchange-Traded Self-Indexe… 0.88% 87,427 SH 8 สิงหาคม 2026 รายวัน
AKAF · ETF Series Solutions 0.84% 271 NS 31 พฤษภาคม 2026 N-PORT
FNDB · SCHWAB STRATEGIC TRUST 0.83% 120,850 NS 31 พฤษภาคม 2026 N-PORT
RECS · Columbia ETF Trust I 0.81% 529,096 NS 30 เมษายน 2026 N-PORT
FEUS · FlexShares Trust 0.81% 10,773 NS 30 เมษายน 2026 N-PORT